A 33.9% reduction in pulmonary vascular resistance from a four-patient subgroup is exactly the kind of number that demands context before excitement — and the context here is genuinely interesting. Quince Therapeutics presented Phase 2a data for LAM-001, an inhaled rapamycin formulation, at ATS showing that in PH-ILD patients who remained symptomatic on background treprostinil therapy, add-on LAM-001 produced a 67.4-meter gain in six-minute walk distance and a 28.8% drop in NT-proBNP at 24 weeks. All six evaluable patients across the broader PH cohort transitioned from Functional Class III to Class II by week 24. These are striking directional signals — but only six patients were evaluable at the primary endpoint, four in the PH-ILD subgroup, and the trial was open-label with no control arm.
What makes LAM-001 mechanistically distinct is the inhaled delivery strategy. Systemic mTOR inhibition with oral sirolimus carries a well-documented immunosuppressive and metabolic toxicity burden that has historically limited its clinical utility in pulmonary vascular disease. By depositing rapamycin directly into the lung parenchyma and vasculature, this formulation targets the mTOR-driven smooth muscle cell proliferation and fibroblast activation that drive vascular remodeling and fibrosis simultaneously — a dual mechanism that is biologically coherent for PH-ILD, where both processes co-evolve. The tolerability profile in this small cohort appeared acceptable on top of stable prostacyclin therapy, which is the clinically relevant combination.
The design limitations are real but appropriate for Phase 2a. Open-label, ten patients enrolled with six evaluable, four sites — this is hypothesis generation, not confirmation. The FVC improvement of 1.8% in the PH-ILD subgroup is modest and does not independently validate an anti-fibrotic lung effect; it is a trend at best. The company is moving directly into a Phase 2b trial targeting mid-2026 initiation, with topline data expected in Q1 2028. That timeline gives roughly 18 months of execution before the investment community reassesses, and the trial design — including whether it incorporates a randomized control arm, blinding, and event-driven endpoints — will determine whether this data package can support a registration pathway or requires yet another confirmatory step.
The single number to watch when Phase 2b design details emerge is the PVR endpoint structure: whether it anchors to exercise-state or resting supine measurements will signal how aggressively Quince is willing to design for regulatory relevance versus statistical tractability.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
